BNET Industries
Market Cap:$119.9M
Last Fiscal Year Sales:$99.5M
- Public
Dow Jones Description
China is the epitome of "risky business". Numerous Fortune 100 companies have failed disastrously in China, and the "balance sheet" since the post-Tiananmen Square massacre is surfeit with (appropriately) red ink. So why and how will Genesis succeed? The odds for success are long and discouraging. Yet, we believe that we can mitigate against some of the risks by having created a revitalized business network, by late 2005, that might deliver handsome rewards. No fellow adventurer should join us, however, unless, in addition to the daunting challenges, a true commitment to patience and dedication is at the very forefront. Success in China takes years, if ever it is to be realized. In addition to experienced management in Beijing and the US, Genesis has developed important professional ties in both hemispheres. As the "Year of the Golden Pig" celebration approached on February 18, 2007, Genesis China engaged a media company to research the Company and provide a comprehensive, updated Profile. Although compensated by Genesis, the researcher did furnish an abundance of useful information that could assist interested parties in formulating informed, objective opinions about the Company. In August 2006, Genesis China formally joined the United States Chamber of Commerce, headquartered near the White House in Washington D.C. As an active member amongst its 3 million participating companies and organizations, Genesis China believes that this USCC membership could significantly add...
Chairman and Chief Executive Officer
Wubo CaoNumber of Employees 440
Contact Information
Middle Section Longmao Street Area A Laiyang
Yantai 265200
(86) 535 7282997
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
-
Jiangbo Pharmaceuticals Announces Resignation of Chief Operating Officer
-
Jiangbo Pharmaceuticals Announces Record Fourth Quarter and Fiscal Year 2009 Results
-
Jiangbo Pharmaceuticals Guides Below Estimates
News & Analysis
Filter by
genesis pharmaceuticals enterprises inc. - All News and Analysis
Rio's Cloud Peak Down in Debut
By Clare Baldwin and Phil WahbaNEW YORK (Reuters UK) - Investors bet on growth in the IPOs of a Chinese hotel chain and an online education company on Friday, but were less enthusiastic about a spin-off of mining giant Rio Tinto.Rio Tinto's U.S. coal-mining spin-off, Cloud Peak Energy Inc CLD...
Rio's Cloud Peak IPO Edges Down, 3 Other IPOs Up
By Clare Baldwin and Phil WahbaNEW YORK (Reuters) - Investors bet on growth on Friday, bumping up shares in two newly listed companies with strong trajectories while remaining neutral or down on two others whose prospects are murkier.Mining giant Rio Tinto's spin-off Cloud Peak Energy Inc CLD edged down in...
Mixed Day For IPOs as Rio Unit Disappoints
By Clare Baldwin and Phil WahbaNEW YORK (Reuters) - Investors proved to be selective as four U.S.-listed initial public offerings priced either below or at their expected ranges on Thursday evening.The largest IPO came from Cloud Peak Energy Inc CLD, the U.S. coal mining unit of Anglo-Australian miner Rio Tinto...
Investing in Homeland Security: Global Defense Technology & Systems IPO
Abbi Adest submits: Global Defense Technology & Systems GTEC, a provider of IT and engineering services to US defense and intelligence agencies, is expected to price its IPO this week. Business Overview from prospectus by SA Editor Abbi Adest
Genesis Pharmaceuticals Enterprises F2Q09 (Qtr End 12/31/08) Earnings Call Transcript
Question-and-Answer SessionOperator Yes ma'am. Operator Instructions. And your first question comes from the line of Dimitri Wagner from Genesis Pharmaceuticals ph. You may proceed. Unidentified Analyst Good morning, Elsa and the rest of the Board. Sung Elsa Good morning. Unidentified Analyst Good morning, Elsa. I have a couple of...
Genesis Pharmaceuticals Enterprises, Inc. F1Q09 (Qtr End 09/30/08) Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions. And your first question comes from the line of [Louis Mark]. Please proceed. Louis Mark Sure. Thank you for taking my calls. First of all, congratulations on the very impressive sales performance for the past quarter. My first question is regarding your revenue breakdown....
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Adam Wasserman | Chief Financial Officer |
| Haibo Xu | Coo |
| Sung Elsa | Cfo |
| Jingsheng Xin | Vice President&Director of Equipment |
| Lining Dong | Vice President&Director of Technology |
| Weidong Yang | Vice President&Director of Sales |
| Xin Jingsheng | Vice President & Director, Equipment |
| Robert Cain | Outside Director |
| Rodrigo Arboleda | Outside Director |
| Hong Xue | Financial Controller |
| Kenneth Clinton | Director |
| Li Shaoqing | Director |
| Robert Zhuang | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Wubo Cao | Chairman and Chief Executive Officer |
| John Yang Wang | Board of Directors |
| Michael Marks | Board of Directors |
| Xiaowei Feng | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Chairman and Chief Executive Officer | Current |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Chief Financial Officer | Current |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Coo | Current |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Cfo | Current |
| American Institute of Certified Public Accountants | Board of Directors | Current |
| CFO Oncall, Inc. | Vice President | Former |
| Applica Consumer Products, Inc. | Senior Internal Auditor | Former |
| Sherb & Co., Llp | Former |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Vice President&Director of Equipment | Current |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Vice President&Director of Technology | Current |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Vice President&Director of Sales | Current |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Vice President & Director, Equipment | Current |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Outside Director | Current |
| Talkingstocks.Com, LLC | Director | Current |
| JIANGBO PHARMACEUTICALS, INC. | Board of Directors | Current |
| Wharton Graduate School of the University of Pennsylvania | MBA | Former |
Mr Arboleda has served as a director of the Registrant since November 30, 2006 and continue to serve as a director of the combined entity. Mr Arboleda has 40 years of experience in top executive positions in the private sector and is currently a partner in Miami-based Globis Group, LLC ("Globis"). Globis is a business development firm for the Ibero-American market, China and the United States. Among its current projects is securing a network of distributorships in Latin America for AMI-First Automotive Works, the largest vehicle manufacturer in China. In addition, Globis seeks opportunities for the Exxel Group, a large private equity fund based in Argentina. Prior to forming Globis, Mr Arboleda was the Executive VP of Ogden Corporation of NY, a Fortune 100 Service multinational corporation with worldwide interests in Aviation, Energy and Entertainment. Mr Arboleda was responsible for the Business Development efforts in Latin America and Spain for almost 10 years. He lead the efforts of opening 10 bases of airport services in Latin America and in Spain, of being awarded the largest airport management privatization project in the world, 33 airports in Argentina, in consortium with Malpensa 2000 of Milan, Italy, and a local Argentinean entrepreneur. He directed the construction of the largest Fair and Exhibit complex in Latin America, at La Rural de Palermo, in Buenos Aires, Argentina, a joint venture with the emblematic Sociedad Rural Argentina. Mr Arboleda holds a Bachelor of Architecture degree from MIT.
| Organization | Position | Status |
|---|---|---|
| Globis LLC | Founder | Current |
| JIANGBO PHARMACEUTICALS, INC. | Outside Director | Current |
| JIANGBO PHARMACEUTICALS, INC. | Board of Directors | Former |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Financial Controller | Current |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Director | Current |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Director | Current |
Mr. Michael Marks, began serving as an independent Director on October 10, 2007. He is currently a managing director and principal of Sonnenblick Goldman Asia Pacific Limited, a firm that provides advisory services in real estate investments. Mr. Marks is also the President and Director of Middle Kingdom Alliance Corp., a special purpose acquisition corporation listed on Over-the-Counter Bulletin Board. Previously, Mr. Marks served as a director of Horwath Asia Pacific from January 2002 to December 2005 and was the Chief Executive Officer and Director at B2Gglobe (Pty) Limited from May 2001 to December 2002. Mr. Marks received both bachelor's and master's degrees in Commerce from the University of the Witwatersrand in Johannesburg, South Africa in 1994 and 1997, respectively, and also received a bachelor's degree in Psychology from the University of South Africa in 1998.
| Organization | Position | Status |
|---|---|---|
| Middle Kingdom Alliance Corp. | President | Current |
| China Housing & Land Development, Inc. | Board of Directors | Current |
| JIANGBO PHARMACEUTICALS, INC. | Board of Directors | Current |
| Middle Kingdom Alliance Corp. | Director | Current |
| Land Development, Inc. | Director | Current |
| University of the Witwatersrand | Master's Degrees In Commerce | Former |
| University Corp. | Bachelor's Degree In Psychology | Former |
| University of the Witwatersrand | Bachelor's | Former |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Director | Current |
| Organization | Position | Status |
|---|---|---|
| JIANGBO PHARMACEUTICALS, INC. | Board of Directors | Current |
Executive News
-
Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009
| Volume | 9,212 |
| Shares Outstanding | 11.6M |
| Market Cap | 119.9M |
| Year High | 14.25 |
| Year Low | 3.40 |
| Earnings Per Share | 1.43 |
| P/E Ratio | 7.23 |
| Dividend | 0.00 |
| Yield | 0.00 |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes


